• Featured Product
  • KD/KO Validated

MCL1 Monoclonal antibody, PBS Only (Capture)

MCL1 Monoclonal Antibody for WB, IHC, IF/ICC, Cytometric bead array, Indirect ELISA

Host / Isotype

Mouse / IgG2b

Reactivity

human

Applications

WB, IHC, IF/ICC, Cytometric bead array, Indirect ELISA

Conjugate

Unconjugated

CloneNo.

1E3C2

Cat no : 66026-1-PBS

Synonyms

Induced myeloid leukemia cell differentiation protein Mcl-1, EAT, Bcl-2-related protein EAT/mcl1, Bcl-2-like protein 3, Bcl2-L-3



Product Information

66026-1-PBS targets MCL1 as part of a matched antibody pair:

MP50655-1: 66026-1-PBS capture and 66026-2-PBS detection (validated in Cytometric bead array)

Unconjugated mouse monoclonal antibody pair in PBS only (BSA and azide free) storage buffer at a concentration of 1 mg/mL, ready for conjugation.

This conjugation ready format makes antibodies ideal for use in many applications including: ELISAs, multiplex assays requiring matched pairs, mass cytometry, and multiplex imaging applications.Antibody use should be optimized by the end user for each application and assay.

Tested Reactivity human
Host / Isotype Mouse / IgG2b
Class Monoclonal
Type Antibody
Immunogen MCL1 fusion protein Ag10609
Full Name myeloid cell leukemia sequence 1 (BCL2-related)
Calculated Molecular Weight 350 aa, 37 kDa
Observed Molecular Weight35 kDa
GenBank Accession NumberBC107735
Gene Symbol MCL1
Gene ID (NCBI) 4170
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS Only
Storage ConditionsStore at -80°C.

Background Information

MCL-1 is an anti-apoptotic member of the Bcl-2 family originally isolated from the ML-1 human myeloid leukemia cell line. Similar to BCL2 and BCL2L1, MCL1 can interact with BAX and/or BAK1 to inhibit mitochondria-mediated apoptosis. Mcl-1 is critical for the proliferation and survival of myeloma cells in vitro, and overexpression of Mcl-1 protein in myeloma cells is associated with relapse and short event-free survival in multiple myeloma patients. Recent studies show that MCL-1 is upregulated in numerous haematological and solid tumour malignancies. Therefore, MCL-1 has been suggested as a potential new therapeutic target.